← Human Trials & Peer-Reviewed Studies
Usefulness of N-terminal pro-brain natriuretic peptide and C-reactive protein to predict ICU mortality in unselected medical ICU patients: a prospective, observational study
Plain-language guide to PMID 21272380 (2011): clinical trial study of BNP (Nesiritide) in 576 patients.
Key Facts
- PMID
- 21272380
- Journal
- Critical care (London, England)
- Year
- 2011
- Study type
- Clinical Trial
- Authors
- Wang F et al. (6 authors)
- DOI
- 10.1186/cc10004
What This Study Did, in Plain Language
What Was Tested
Researchers studied BNP (Nesiritide) in this clinical trial publication.
The researchers aimed to assess the prognostic value of NT-proBNP, CRP or the combination of both in unselected medical ICU patients.
Why It Was Studied
The performance of N-terminal pro-brain natriuretic peptide (NT-proBNP) and C-reactive protein (CRP) to predict clinical outcomes in ICU patients is unimpressive.
Who Took Part
According to the abstract, 576 patients were involved.
The age groups tagged for this paper are middle-aged adults, older adults and people over 80, both men and women.
A total of 576 consecutive patients were screened for eligibility and followed up during the ICU stay.
The researchers collected each patient's baseline characteristics including the Acute Physiology and Chronic Health Evaluation II (APACHE-II) score, NT-proBNP and CRP levels.
How the Study Was Run
The primary outcome was ICU mortality.
Potential predictors were analyzed for possible association with outcomes.
What Was Measured
The performance of N-terminal pro-brain natriuretic peptide (NT-proBNP) and C-reactive protein (CRP) to predict clinical outcomes in ICU patients is unimpressive.
PubMed files the paper under topics including Biomarkers, C-Reactive Protein, Critical Care, Hospital Mortality, Intensive Care Units, Natriuretic Peptide, Brain and Peptide Fragments.
What This Means in Plain Language
This is a clinical trial of BNP (Nesiritide) in 576 patients.
With several hundred people or more, it is a fairly large study for this kind of research.
The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2011 (Critical care (London, England)), a journal based in England.
More context: the BNP (Nesiritide) compound page, all human trials.
Our Notes on the Compound
BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.